The National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) are seeking proposals for the translation of novel cancer-specific imaging agents and techniques to mediate successful image-guided cancer interventions. The goal of this solicitation is to improve imaging sensitivity to detect small tumor cell masses (1 mm3) in humans. The proposed research should focus on translating improvements in imaging sensitivity to a clinical environment and demonstrating the detection of small tumor cell aggregates in cancer patients. The solicitation supports the development and validation of activatable agents and/or techniques for sensitive cancer detection in human subjects. The budget for Phase I is up to $400,000 for 12 months, and for Phase II, it is up to $2,000,000 for 2 years. The solicitation is closed, and the application due date was November 14, 2023. For more information, refer to the solicitation link.